Cargando…
Not all SARS-CoV-2 IgG and neutralizing antibody assays are created equal
Autores principales: | Lippi, Giuseppe, Plebani, Mario |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8702590/ https://www.ncbi.nlm.nih.gov/pubmed/34958752 http://dx.doi.org/10.1016/j.cca.2021.12.020 |
Ejemplares similares
-
Answer to the letter of Lippi & Plebani entitled “Not all SARS-CoV-2 IgG and neutralizing antibody assays are created equal”
por: Malipiero, Giacomo, et al.
Publicado: (2022) -
Not all therapeutic antibody isotypes are equal: the case of IgM versus IgG in Pertuzumab and Trastuzumab
por: Samsudin, Firdaus, et al.
Publicado: (2020) -
The presence of anti–SARS-CoV-2 antibodies does not necessarily reflect efficient neutralization
por: Lippi, Giuseppe, et al.
Publicado: (2022) -
Activation of SARS-CoV-2 neutralizing antibody is slower than elevation of spike-specific IgG, IgM, and nucleocapsid-specific IgG antibodies
por: Takahashi, Maika, et al.
Publicado: (2022) -
Robust validation and performance comparison of immunogenicity assays assessing IgG and neutralizing antibodies to SARS-CoV-2
por: Bonhomme, Marie E., et al.
Publicado: (2022)